uploads///Chart  Neuro

Eli Lilly’s Neuroscience Products Portfolio in 3Q17

By

Jan. 2 2018, Updated 2:01 p.m. ET

Neuroscience products

Eli Lilly and Company’s (LLY) human pharmaceuticals segment includes neuroscience drugs Strattera, Cymbalta, and Zyprexa. All of them reported lower sales in 3Q17, thus impacting Eli Lilly’s growth.

The above chart shows revenues for Eli Lilly’s neuroscience products for the last eight quarters.

Article continues below advertisement

Strattera

Strattera is a neuroscience drug for attention-deficit disorder and hyperactivity disorders. Strattera had revenues of $137 million in 3Q17, a decline of ~31% compared to $199 million in 3Q16. The decline was driven by lower US sales, partially offset by strong international sales. US sales decreased 56%, while international sales increased 6%.

Cymbalta

Cymbalta is an antidepressant drug. It had revenues of $183.2 million in 3Q17, a decline of 42% compared to $313.5 million in 3Q16. The decline was driven by lower US sales and a 5% negative impact of foreign exchange, partially offset by strong international sales. US sales declined 88%, while international sales increased 8%.

Zyprexa

Zyprexa is an antipsychotic drug. It reported revenues of $141 million in 3Q17, a decline of 6% compared to $149 million in 3Q16. The decline was driven by lower international sales, partially offset by strong US sales. US sales rose 72%, while international sales fell 10%.

The Vanguard Health Care ETF (VHT) holds 39.8% of its total investments in pharmaceutical companies. It has 2.3% of its total investments in Eli Lilly (LLY), 2.6% in Gilead Sciences (GILD), 3.5% in Amgen (AMGN), and 5.8% in Pfizer (PFE).

Advertisement

More From Market Realist